---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-213440"
form_type: "8-K"
ticker: "CGON"
cik: "0001991792"
company_name: "CG Oncology, Inc."
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T21:13:11.327967+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CG Oncology Q1 net loss widens to $60.2M; BLA submission on track for Q4 2026

## Summary
- Net loss of $60.2M ($0.71 per share) vs $34.5M ($0.45) in Q1 2025.
- Cash, cash equivalents & marketable securities $1.1B as of March 31, 2026; includes $391.4M from ATM sales.
- BLA for cretostimogene in HR BCG-unresponsive NMIBC expected to complete in Q4 2026 after FDA alignment.
- Phase 3 PIVOT-006 topline data in intermediate-risk NMIBC anticipated 1H 2026.
- Appointed Jim DeTore as CFO in April 2026; he brings 30+ years life sciences experience.

## SEC filing metadata
- accession: 0001193125-26-213440
- form_type: 8-K
- ticker: CGON
- cik: 0001991792
- company_name: CG Oncology, Inc.
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1991792/000119312526213440/0001193125-26-213440-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1991792/000119312526213440/ck0001991792-20260508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-213440
- JSON: https://secwatch.observer/filing/0001193125-26-213440.json
- Plain text: https://secwatch.observer/filing/0001193125-26-213440.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.